Navigation Links
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new six month safety and efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. Consistent with previously reported six month (Petal Study) and three month (Lilac Petal Study) results, a favorable safety profile and clinically meaningful efficacy have again been confirmed through month six of the Lilac Petal Study. This newly available data also provides clinical confirmation of Neurocrine's extensive pharmacologic modeling related to the elagolix dose-response continuum. The outcome of primary interest at month six was the impact of the elagolix 250 mg dose on bone mineral density (BMD) as measured by dual energy X-ray absorptiometry (DXA) scanning.

Over the six month treatment period, elagolix 150 mg once daily had minimal impact on BMD (-0.80% mean change from baseline, femur; -0.66% mean change from baseline, spine). The 250 mg once daily dose, as expected, had slightly greater percentage change from baseline at month six (-1.0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is consistent with that previously demonstrated in the six-month Petal Study.

"We selected the 150 mg and 250 mg once daily doses for this study based upon predictions generated from extensive modeling of dose, estradiol and bone mineral density relationships. Prior to this study we anticipated that the 250 mg dose would provide exposure such that we would start to see an increased impact on bone mineral density in a small portion of study subjects. The Lilac Petal data confirm that our modeling of the dose-response curve was accurate," said C
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
2. Blue Marble Energy Corp. Announces Successful Close of Series A Financing
3. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
4. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
5. Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UKs Veterinary Laboratories Agency
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
8. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
9. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
10. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... San Diego, CA, and Bellingham, WA (PRWEB) August ... nanoscience and optical engineering, visions for next-generation wearable ... Light 2015 among numerous highlights at this year’s ... in the San Diego, California, Convention Center. More ... suppliers last week attended conferences, courses, an exhibition, ...
(Date:8/26/2014)... and REHOVOT, Israel , August 26, ... 3D printing specialist, Replica 3DM, supports NHS hospitals with surgery ...   - Performing surgery on 3D ... times; improves patient recovery and provides an effective aid for ... Ltd. (Nasdaq: SSYS ), a global leader ...
(Date:8/26/2014)... CA (PRWEB) August 26, 2014 The ... USD 8,020.1 million by 2020, according to a new ... personalized medicine and theranostics, and the subsequent introduction of ... factors driving market growth over the next six years. ... chronic diseases such as cancer, coupled with disease triggering ...
(Date:8/26/2014)... Aug. 26, 2014  Guardant Health, a healthcare ... oncology diagnostic products, has been recognized today by ... Technology Pioneer . As an innovator in non-invasive, ... companies across a wide variety of industries and ... Guardant360 ® , Guardant Health,s first commercially ...
Breaking Biology Technology:Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2
... , Newly Launched Donor Network Alliance Achieves Company & Industry ... June 24 Through a unique and effective collaboration of ... Network Alliance (DNA) - the industry,s first ever web-based collective ... largest egg donation resources in the country with more than ...
... Release Highlights, - Melogliptin continues to demonstrate potential to be ... incidence of, hypoglycemia and neutral effect on body ... end 2009, - IND approved by USFDA, ... Indian company to have a truly global innovative drug for the ...
... PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today announced through ... planning to construct a manufacturing facility in the State ... , , According to a recent Forbes Magazine ... abundance of biomass in Georgia,s Bioenergy Corridor ranks third ...
Cached Biology Technology:First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S. 2Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials 2Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 2Natural Fuels Industries Eyes 'Biomass Rich' Georgia for Production Facility 3
(Date:8/26/2014)... feeding patients through a tube, in an intensive care ... practice of a certain amount of feeding per hour ... to a volume-based system, which calls for a certain ... a system was found to be effective in ICU ... the American Society for Parenteral and Enteral Nutrition,s (A.S.P.E.N.) ...
(Date:8/26/2014)... Unregulated trash burning around the globe is pumping far ... records. A new study led by the National Center ... of the world,s garbage is burned in such fires, ... health and climate change. , The new study provides ... pollutants such as particulates, carbon monoxide, and mercury that ...
(Date:8/26/2014)... an increased risk of autism among children of ... reflect the known increased risk associated with severe ... online publication in Molecular Psychiatry , investigators ... while a diagnosis of autism spectrum disorder was ... antidepressants during pregnancy than in those with no ...
Breaking Biology News(10 mins):Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3
... New Rochelle, NY, October 30, 2009Sponsored by ... by BioConferences International, Inc., GREENBioPharma is the first ... and technologies available for sustainable life science organizations. ... and methods, but also on the economic rationales ...
... the fight against the deadly Hendra virus following the development ... lives of people who become infected with the virus. ... demonstrated that administering human monoclonal antibodies after exposure to Nipah ... from challenge in a disease model. According to CSIRO,s ...
... around the world are becoming more like the highly diverse ... has led UOG professors Thomas Marler and Seyda Turk-Smith to ... of teaching to a group of learners with a range ... and learning more about how my psychology research can be ...
Cached Biology News:Breakthrough in fight against Hendra virus 2Multicultural education focus of new UOG publication 2
... a commonly used technique for studying protein ... electrophoresed on SDS-PAGE and transferred to a ... they are probed with specific antibodies. Unlike ... of Southern and Northern blots, it has ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
Biology Products: